Background: The proteomics approach is the new mantra in disease biomarker research in areas such as
major depression (MD). Current protocols for investigating biomarkers in biological fluid often employ both immuno-
based and non-immuno-based technologies.
Method: The immuno-based method is used normally in measuring well-known disease biomarkers, and commercial
kits are often available. Immuno-based methods such as radio-immunoassay and enzyme-linked immunosorbent
assay are sensitive and specific. However, tedious sample preparations such as filtration and centrifugation are required.
Non-immuno-based technologies, such as matrix-assisted laser desorption/ionization- time of flight mass
spectrometry has been proven to be useful techniques to rapidly screen disease biomarkers in human biological fluids.
The mass spectrometer provides a powerful research tool in the proteomics field, not only in biomarker discovery
but also in biomarker validation. A bioinformation tool like principal component analysis is a statistical procedure
that utilizes proteomics data.
Conclusion: In this article, we review the proteomics approaches in MD biomarker research and the data after the
antidepressants treatment. And it covers a selection of advances in the realm of proteomics and its promise for major
depression biomarker discovery and antidepressant effects. These technologies have opened new approaches to identifying
signaling biomarkers associated with the cellular metabolism, cell life cycle, and detection of disease.